CJC-1295 + Ipamorelin vs CJC-1295 (without DAC)

CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin is a dual-peptide formulation combining a growth hormone-releasing hormone (GHRH) analogue with a selective growth hormone secretagogue receptor (GHSR/ghrelin receptor) agonist. These two peptides operate through complementary mechanisms: CJC-1295 (without DAC) stimulates GH release by binding GHRH receptors on pituitary somatotrophs and amplifying the baseline GH pulse, while ipamorelin activates the ghrelin receptor to initiate a separate GH release signal. When used together, research indicates a synergistic amplification of GH pulsatility that exceeds the additive effects of either peptide alone. This synergy was characterized in studies examining GHRH-GHRP combined use, where combined studies produced GH peaks 2-3 times greater than single-agent studies (Bowers et al., Endocrinology). Ipamorelin is distinguished among ghrelin mimetics by its high selectivity for GH release without significantly elevating cortisol, prolactin, or ACTH levels, as demonstrated in clinical studies (Raun et al., European Journal of Endocrinology, 1998). CJC-1295 without DAC has a half-life of approximately 30 minutes, producing acute GH pulses rather than sustained elevation. Compared to GHRP-6, which broadly activates ghrelin receptors causing appetite stimulation, ipamorelin offers cleaner GH release profiles. Store lyophilized powder at -20C; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 28 days. This combination is widely studied by endocrinology research labs, sports medicine institutions, and body composition research centers investigating modulated GH secretagogue studies.

CJC-1295 (without DAC)

CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF) is a synthetic 29-amino acid peptide analogue of growth hormone-releasing hormone (GHRH) with four amino acid substitutions (positions 2, 8, 15, and 27) that confer resistance to DPP-IV enzymatic degradation. Its mechanism of action involves binding to GHRH receptors (GHRH-R) on anterior pituitary somatotroph cells, stimulating cAMP-mediated signaling that triggers growth hormone synthesis and secretion. The amino acid modifications extend the peptide's biological half-life from under 10 minutes (native GHRH) to approximately 30 minutes, enabling meaningful GH pulse amplification while still preserving physiological pulsatile release patterns. Research on this modified GHRH analogue demonstrates it produces GH elevations within 15-30 minutes of use, with return to baseline within 2-3 hours, mimicking natural GH pulse kinetics. Studies suggest CJC-1295 without DAC may support skin thickness and collagen production through GH-mediated IGF-1 elevation (Ionescu and Bhatt, Growth Hormone and IGF Research). Compared to the DAC-conjugated version (CJC-1295 with DAC), the non-DAC form produces shorter, more discrete GH pulses rather than sustained 7-10 day GH elevation, which some research studies prefer for mimicking physiological patterns. It is frequently paired with ghrelin mimetics like ipamorelin for synergistic effect. Store lyophilized powder at -20C; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 21 days. This peptide is studied by endocrinology research departments, cellular-aging medicine laboratories, and body composition research centers investigating GHRH axis modulation.

Frequently Asked Questions